Business
Cambridge Parsortix Laboratory
Cambridge Parsortix Laboratory.
About this update from Cellbxhealth Plc
[{"type":"text","content":"\n \nRNS Number : 4459X Angle PLC 13 January 2014 \n \n\n\n\n\n\nFor immediate release \n \n\n\n13 January 2014\n\n\n\n\n \nANGLE plc \n \nCAMBRIDGE PARSORTIX LABORATORY\n \nANGLE plc (AIM: AGL), the specialist medtech company, is pleased to announce an agreement with the Medical Research Council's Cancer Unit at the University of Cambridge to establish a laboratory facility that will allow research teams in the Unit, and the wider scientific community at the University of Cambridge, to have improved access to the Parsortix system.\n \nThe facility will allow researchers in Cambridge to investigate applications of the Parsortix system in the diagnosis and treatment of several forms of cancer. ANGLE is supporting this activity through the provision of Parsortix machines and a contribution to the costs of employing a full-time technician. \n \nANGLE's primary objective in establishing this agreement is to support the Company's aim of achieving widespread market adoption of the Parsortix system in clinical practice. The Cambridge facility will aid ANGLE in identifying key clinical applications, in securing positive clinical data demonstrating the medical utility of those applications in patient trials, and in obtaining Key Opinion Leader support for the adoption of Parsortix in the routine medical care of cancer patients. \n \nANGLE's Founder and Chief Executive, Andrew Newland, commented:\n\"The MRC Cancer Unit at the University of Cambridge is a world-leader in cancer research and treatment. We are delighted that its researchers have chosen to focus on ANGLE's Parsortix system for the capture of circulating tumour cells (CTCs) for analysis in pursuit of personalised cancer treatment to improve outcomes for patients.\"\n \nMRC Cancer Unit Director, Professor Ashok Venkitaraman, commented:\n\"This agreement will greatly facilitate the use of ANGLE's Parsortix system in our research, and that of other colleagues in Cambridge. We foresee several exciting research avenues to test different applications of the Parsortix system in the diagnosis and personalised treatment of cancer.\" \n \n \n \n \nFor further information:\n \n\n\n\n\nANGLE plc\n\n\n01483 685830\n\n\n\n\nAndrew Newland, Chief Executive\nIan Griffiths, Finance Director\n \n\n\n\n\n\n\n...